Abstract
Novo-Nordisk A/S will report quarterly results on November 4, 2026, Pre-MKt; our preview synthesizes recent financial data, management’s latest projections, and prevailing Street sentiment to frame what the market is likely to focus on and how the numbers may stack up against expectations.Market Forecast
Based on the latest projections, Novo-Nordisk A/S is expected to deliver revenue of 73.94 billion Danish kroner this quarter, a year-over-year decrease of 5.20%, with estimated EPS of 4.90 (up 6.94% year over year) and estimated EBIT of 23.11 billion Danish kroner (down 8.65% year over year). No formal forecast for gross profit margin or net profit margin is available in the current guidance set, so comparisons for margins are not included here.The core business is projected to be supported by ongoing demand for the company’s diabetes and obesity therapies, with management emphasizing continued uptake in key markets; the outlook suggests a measured quarter as supply chain execution and new product rollouts shape near-term momentum. Within the portfolio, Diabetes and Obesity Care remains the most promising segment, contributing 73.58 billion Danish kroner last quarter; while segment-specific year-over-year growth was not disclosed, recent utilization data and new modality launches are key indicators for growth trajectory.
Last Quarter Review
Novo-Nordisk A/S reported last quarter revenue of 78.49 billion Danish kroner, a gross profit margin of 78.21%, net profit attributable to the parent company of 20.99 billion Danish kroner (net profit margin 26.74%), and adjusted EPS of 4.75, with revenue up 2.12% year over year and EPS down 20.30% year over year. On a sequential basis, net profit decreased by 56.77%, reflecting a softer quarter-over-quarter comparison despite resilient top-line performance.A key highlight was that revenue modestly exceeded the prior-year period, supported by continued uptake in diabetes and obesity medicines and new delivery formats, which offset localized softness and spending discipline elsewhere. By business line, Diabetes and Obesity Care generated 73.58 billion Danish kroner and Rare Disease contributed 4.91 billion Danish kroner, underscoring the dominance of the GLP-1-led portfolio in the company’s mix.
Current Quarter Outlook (with major analytical insights)
Main Business Outlook
Management’s latest guidance points to a quarter where demand for the company’s GLP-1 therapies continues to anchor revenue. The forecast of 73.94 billion Danish kroner implies a 5.20% year-over-year decline in total revenue, a reflection of a high base and near-term balancing in channel inventories and promotional cadence rather than a demand shortfall. In parallel, the EPS estimate of 4.90 suggests year-over-year growth of 6.94%, indicating anticipated operating leverage and disciplined cost control, even as EBIT is expected to decline 8.65% year over year to 23.11 billion Danish kroner. The combination of lower revenue but higher EPS estimate points to a mix of lower input variance, product mix optimization, and possibly tighter operating expenses more than offsetting topline moderation.Execution around GLP-1 availability and format options remains central. Recent updates pointed to solid adoption of oral semaglutide formulations, as evidenced by real-world datasets showing meaningful weight reductions after switching to oral therapy over a three-month period. That operationalizes a strategy to broaden access through varied delivery routes. Additionally, new data readouts for pipeline combinations and next-generation therapies set the stage for future differentiation, though they may not yet translate into current-quarter revenue. The company must also navigate competitive messaging in the United States, where a legal attempt to restrain a rival’s comparative advertising was not successful; the commercial teams will need to sharpen in-market execution, physician engagement, and patient support initiatives to sustain share without resorting to aggressive pricing actions.
From a financial lens, the forecast tilt suggests margins could remain resilient despite the anticipated revenue softness. Last quarter’s gross margin printed at a high 78.21% and the net margin at 26.74%, and while forward-looking margin guidance is not provided, product mix, incremental production efficiencies, and disciplined SG&A could keep profitability ratios aligned with medium-term targets. A cushion comes from the portfolio’s favorable unit economics and scale effects, even as the company carefully calibrates inventory and rollout pacing across geographies.
Most Promising Business Outlook
Diabetes and Obesity Care remains the most promising area, delivering 73.58 billion Danish kroner last quarter and underpinning overall performance. This franchise continues to benefit from rising prescription volumes, the broadening of formulations (including oral options), and ongoing geographic expansion. While the most recent filing did not disclose a year-over-year growth rate for the segment, multiple operating indicators point to sustained utilization growth and increased patient adherence, especially where access programs and distribution networks have matured.The differentiation strategy emphasizes clinical breadth and real-world evidence. Recent clinical news, including investigational therapies demonstrating substantial weight reduction outcomes across trials, contributes to physician confidence and could drive durable demand once approved and launched. Complementary real-world evidence supports the therapeutic profile in metabolic outcomes, and selective regulatory milestones—such as new approvals for related indications—reinforce a path for label expansions or adjunctive use. Even though these wins are not instant revenue catalysts, they shape the narrative for medium-term growth and reinforce the franchise’s positioning within the company’s mix.
Commercially, the segment’s execution will be assessed through refill rates, initiation growth, and the relative contribution of new formulations to total prescriptions. The primary risk over the next quarter lies not in demand but in managing the cadence of shipments, ensuring consistent supply across markets, and holding share against more assertive competitor messaging. The interplay of co-pay dynamics, formulary access, and patient onboarding support will also influence quarter-to-quarter variability, even if the long-term trend remains constructive.
Key Stock Price Drivers This Quarter
The most immediate stock price drivers are expected to be: delivery against the company’s own revenue and EPS forecasts; observable momentum in diabetes and obesity prescriptions, including updates on oral formulations; and any new disclosures related to commercialization initiatives or access expansions. Since the forecast implies lower revenue but higher EPS year over year, the market will closely watch gross-to-net trends, expense control, and the implied tax rate to reconcile the profitability path with the topline guide. Any deviation in cost discipline or adverse mix shifts could draw disproportionate attention given how explicitly EPS is expected to rise.Another driver is the competitive landscape in the United States. A recent court decision allowed rival advertising to continue, meaning in-market comparisons may persist through the quarter. Investors will gauge whether comparative messaging by competitors translates into tangible share pressure or if loyalty and efficacy data support stable-to-expanding share for the company’s portfolio. Management commentary around switching dynamics, dose titration persistence, and adherence will be important datapoints for the share-of-voice and share-of-script outlook.
Strategic and corporate actions add a third pillar to potential stock volatility. The company has telegraphed interest in augmenting its portfolio through licensing and development agreements, as seen in collaborations that aim to extend the dosing interval and to add new mechanisms. Announcements around delivery technologies or partnering to diversify the pipeline can be viewed as supportive steps toward medium-term resilience. Additionally, management has discussed options to elevate its capital markets profile, including the possibility of revisiting listing structures to enhance U.S. market engagement. Any tangible progress or updates on that front can influence sentiment independent of pure quarterly numbers, especially after a capital markets day that saw mixed investor reaction.
Analyst Opinions
Opinions collected during the period show a clear tilt toward a bearish stance among directional calls, with multiple Sell ratings and no prominent Buy initiations. That ratio implies bearish opinions are the majority, while several large houses have maintained neutral (Hold) stances rather than endorsing an outright positive view. The consensus shape is therefore skewed toward caution or negativity rather than optimism.Among the more assertive voices, Deutsche Bank’s Emmanuel Papadakis has maintained a Sell rating across several updates, with price targets cited at different times around Danish kroner 265.00, 245.00, and 225.00, and characterized the company’s recent strategic messaging as underwhelming on multiple fronts. The critical tone centers on concerns that guidance and long-term plans lack sufficient detail and that execution milestones remain to be demonstrated to restore full investor confidence. The Sell case also points to the sensitivity of valuation to flawless execution in GLP-1 demand capture, data readouts, and potential market share pressures from a key competitor’s comparative initiatives. These notes emphasize that without clear evidence of accelerating growth beyond the flagship portfolio, the risk-reward could remain fragile in the near term.
Neutral commentary has also been prominent, with J.P. Morgan’s Richard Vosser, UBS’s Matthew Weston, Goldman Sachs’ James Quigley, and DBS’s Nico Chen maintaining Hold ratings and highlighting balanced pros and cons. While these holds are not strictly bearish in the binary sense, they provide a backdrop for the broader caution: the market is looking for confirmation that the company can translate promising pipeline data and new modalities into durable revenue and earnings growth without overreliance on a single therapeutic family. The absence of visible Buy initiations during this window reinforces the directional imbalance toward cautious or negative sentiment.
Putting the pieces together, the majority view anticipates a mixed print: revenue that aligns with a modest year-over-year decline, EPS that shows discipline-driven improvement, and an outlook that hinges on steady GLP-1 execution and credible pipeline de-risking. The bearish camp argues that recent investor communications and legal setbacks in marketing disputes accentuate execution risk, and that valuation still embeds ambitious expectations. From a near-term catalyst perspective, bears will scrutinize whether the company meets or exceeds its own EPS estimate of 4.90, whether revenue lands near the 73.94 billion Danish kroner mark, and whether any qualitative comments ease concerns raised after the capital markets day. Absent a strong guidance upgrade or a definitive operational surprise to the upside, the preponderance of analyst rhetoric suggests limited tolerance for shortfalls and a bias to fade rallies until the company demonstrates sustained acceleration across both topline and pipeline milestones.
In sum, for this earnings event on November 4, 2026, Pre-MKt, the prevailing stance among institutional voices is bearish. The key to challenging that view will be evidence of steady revenue traction despite the guided decline, confirmation that EPS strength reflects durable operating improvements rather than transient effects, and tangible updates that strengthen confidence in the path to broader growth beyond the already-scaled core therapies. If management can credibly connect near-term numbers to a robust medium-term arc—through execution detail, access expansion, and pipeline clarity—the tonal balance of future opinions could shift. Until then, the majority perspective remains skeptical and places the burden of proof on the forthcoming report and commentary.
Comments